Wei Guoqing, Wang Jiasheng, Huang He, Zhao Yanmin
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
J Hematol Oncol. 2017 Aug 18;10(1):150. doi: 10.1186/s13045-017-0516-x.
The past decade witnessed the rapid development of adult B-lineage acute lymphoblastic leukemia (ALL) treatment. Beyond the development of chemotherapy regimens, immunotherapy is starting a new era with unprecedented complete remission (CR) rate. Targeting B-lineage-specific surface markers such as CD19, CD20, CD22, or CD52, immunotherapy has been demonstrating promising clinical results. Among the immunotherapeutic methods, naked monoclonal antibodies (mAbs), antibody-drug conjugate (ADC), bispecific T cell engager (BiTE), and chimeric antigen receptor (CAR) T cells are the main types. In this review, we will examine the emerging preclinical and clinical development on (1) anti-CD20 naked mAbs rituximab, ofatumumab, and obinutuzumab; (2) anti-CD19 ADCs SAR3419 and SGN-CD19A and anti-CD19 BiTE blinatumomab; (3) anti-CD22 naked mAb epratuzumab and anti-CD22 ADC inotuzumab ozogamicin; (4) anti-CD52 naked mAb alemtuzumab; and (5) anti-CD19 CAR T cells. We will discuss their efficacy, adverse effects, as well as future development.
过去十年见证了成人B系急性淋巴细胞白血病（ALL）治疗的快速发展。除了化疗方案的发展，免疫疗法正开启一个具有前所未有的完全缓解（CR）率的新时代。针对CD19、CD20、CD22或CD52等B系特异性表面标志物，免疫疗法已显示出有前景的临床结果。在免疫治疗方法中，裸单克隆抗体（mAb）、抗体药物偶联物（ADC）、双特异性T细胞衔接器（BiTE）和嵌合抗原受体（CAR）T细胞是主要类型。在本综述中，我们将探讨以下方面新出现的临床前和临床进展：（1）抗CD20裸mAb利妥昔单抗、奥法木单抗和奥妥珠单抗；（2）抗CD19 ADC药物SAR3419和SGN-CD19A以及抗CD19 BiTE药物博纳吐单抗；（3）抗CD22裸mAb依帕珠单抗和抗CD22 ADC药物奥英妥珠单抗；（4）抗CD52裸mAb阿仑单抗；以及（5）抗CD19 CAR T细胞。我们将讨论它们的疗效、不良反应以及未来发展。
